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Gastrointestinal (GI) hypomotility and symptoms are common in Scleroderma (SSc) patients yet so far uncorrelated. Eight SSc
patients and matched controls were queried about their GI dysmotility symptoms and quality of life (QoL) and underwent
anorectal motility and sensory tests. Speciﬁc scoring systems were developed for anorectal symptoms and anorectal dysmotility.
We found that (1) the SSc patients showed low QoL and marked overall GI symptoms. The most common anorectal symptom
was incomplete bowel movement (50%). (2) Compared to normal controls, SSc patients showed impaired anorectal pressures,
sensations, and rectal compliance (P ≤ .01 for each). (3) The anorectal motility/sensation abnormality score was robustly
correlated with the total anorectal symptom score (rs = .78, P = .02). In conclusion, scleroderma patients have impaired
anorectalmotorandsensoryfunctions,andtheabnormalityscoreoftheseanorectalfunctionsiscorrelated withthetotalanorectal
symptoms score. These scoring systems may assistclinicians in predicting dysmotility based on patient symptoms.
1.Introduction
Systemic sclerosis (SSc, scleroderma) is a multisystemic au-
toimmune disease characterized by prominent widespread
small vessel vasculopathy and endothelial damage with re-
sultant degenerative changes and ﬁbrosis of skin, articular
structures, and internal organs [1, 2]. The exact etiology of
SSc is unknown, but most studies support the hypothesis
that it is an underlying vascular or vasospastic disorder with
strong neuropathic and immunologic inﬂuences [3].
Gastrointestinal (GI) hypomotility involving the entire
gut from the esophagus to the anus is commonly seen in
patients with SSc [4]. Nearly 90% of patients with systemic
sclerosis have at least one upper or lower GI symptom
[5–7]. Anorectal involvement occurs in 50%–70% of SSc
patients [8]. Pathophysiological changes of the gut in SSc
patients occur in two stages: (a) a neuropathic stage, in
which an altered function of enteric nervous system occurs
and (b) a myopathic/ﬁbrotic stage, in which smooth muscle
is gradually lost or atrophied with progressive ﬁbrosis [8].
Details of the pathophysiological changes in the gut of SSc
patients are reviewed elsewhere [9–11].
Although gastrointestinal dysmotility and gastrointesti-
nal symptoms are common in SSc, most studies have failed
to ﬁnd any correlations between GI symptoms and upper
(esophageal) or lower (intestinal or anorectal) dysmotility
[12–15]. Only few studies reported correlations between
one upper or lower GI symptom and gastric or anorectal
functions [16, 17]. We believe that the diﬃculty in estab-
lishing a correlation between symptoms and GI motility
disorders is attributed to the fact that the symptoms and
dysmotility are diverse and not particularly focused on a2 ISRN Gastroenterology
speciﬁc organ or symptom. Accordingly, we hypothesized
that special scoring systems foroverall symptoms and overall
motility/sensory abnormalities would be needed in order to
correlate symptoms with functional abnormalities.
The aims of this preliminary study were (1) to character-
ize abnormalities in anorectal motor and sensory functions
in SSc patients, (2) to develop speciﬁc scoring systems for
anorectal symptoms and anorectal functions, and (3) to
study possible correlations between anorectal symptoms and
abnormalities in anorectal motor and sensory functions.
2.Materialsand Methods
2.1. Subjects. Two groups comprised of SSc patients (N = 8)
and normal controls (N = 8) were included in the study.
The groups were randomly selected and matched for age,
gender, race/ethnicity, and weight, as shown in Table 1.T h e
research protocol was approved by the University of Texas
Medical Branch (UTMB) Institutional Review Board, and
written informed consent was obtained from all subjects
before study entry. All SSc patients satisﬁed the American
College of Rheumatology criteria for Scleroderma [18]. To
t e s tf o rs k i na n do t h e ro r g a ni n v o l v e m e n tb yS S c ,p a t i e n t s
underwent assessment by the Medsger severity index (MSI).
Nine subscales derived from the clinical damage of the
following: general, peripheral vascular, skin, joint/tendon,
muscle, GI tract, lung, heart and kidney, were totaled to
constitute MSI scores. MSI scores were from 0–3 where
0 represented no involvement and 3 represented severe
or end stage involvement [19, 20]. All patients abstained
from prokinetic agents for 72 hours. Controls were selected
form healthy, nonsmoking volunteers reporting rare to no
GI complaints and were on no medications. Subjects were
excludediftheywere(1)unabletogiveinformedconsent,(2)
currently taking prokinetic, anticholinergic or dopaminergic
agents which could potentially modify gastric motility, (3)
pregnant or preparing to conceive a child, and (4) diabetic.
2.2. Experimental Protocol. The subjects underwent a one-
day study performed in the Outpatient Clinical GI Motility
Laboratory at UTMB. On the study day, following an over
night fast, anorectal manometric and sensory tests were
performed, and self-report instruments were ﬁlled out.
2.2.1. Anorectal Motility/Sensation Test. This test included
(1) the measurement of anorectal manometric pressures at
resting, and during squeeze and strain, (2) the measurement
of rectal anal inhibitory reﬂex (RAIR) to phasic rectal dis-
tension at diﬀerent pressures, ranging from 10mL to 60mL,
and (3) rectal sensations to ramp rectal distension, including
the threshold distension volumes for ﬁrst sensation, urge to
defecate, and maximum tolerance [13, 15, 21]. The exact
procedure is described as follows.
The evening before the study, subjects were asked to
inject one hyperosmolar enema in their rectum (Fleet’s
enema, C.B. Fleet Company, Inc. Lynchburg, Va, USA),
evacuate their bowels and fast overnight. The morning
of the study, before coming to UTMB, subjects injected
Table 1: Demographic characteristics of the study populations.
Comparisons between SSc patients and matched normal controls
are performed by Student’s t-test. Data are shown as mean ±
SE, (range of values), or percentages. Mean GI symptoms: mean
of total GI symptoms scored as prevalence, self-reported on the
GI symptoms questionnaire by SSc patients or normal controls.
Daily GI meds: the percentage of subjects per group that are on
daily medication (s) to treat GI symptoms. SF-36 PCS and SF-36
MCS: physical component summary score and mental component
summary score derived from the SF-36 questionnaire.
Variables SSc patients
(N = 8)
Controls
(N = 8) P value
Age, years,
range
59 ± 3
43–68
53 ±3
45–61 .07
Females, %
(number) 75% (6) 88% (7) .3
Postmenopausal, %
(number) 83% (5) 86% (6) .5
Parity in females
(average) 2.3 2.6 .3
Pelvic surgeries
(average) 0.5 0.1 .1
Caucasian %
(Number) 88% (7) 75% (6) .3
Mean weight (lbs) 153 ± 11 160 ±9. 3
Mean disease
duration (yrs) 7.6 ±2N / A
Medsger Severity
index score 5.6 ±1N / A
Mean GI symptoms 17 ± 30 .5 ±0.3 <.01
Daily GI meds % 88% 0% <.01
SF-36 PCS 38 ± 35 4 ±3 .001
SF-36 MCS 48 ± 35 7 ±2. 0 2
a second enema to ensure complete evacuation of their
bowel contents. Upon arrival to UTMB, the subject was
positioned lying in the left lateral position with the hips
ﬂexed.Alubricatedwater-perfused manometry catheterwith
4 pressure sensors staggered at a longitudinal interval of
1cm and a rectal distension balloon ﬁxed to its tip was
inserted through the anus. The catheter was positioned so
that the third sensor (the ﬁrst sensor is the one that is
farthest away from the anus) was in the high pressure zone
(the anal sphincter). The catheter was connected to a com-
puterized manometric system (Polygram Net, Medtronic
A/S, Kobenhavn S, Denmark). The subject was given 10
minutestorelax andbecomeaccustomedtothecatheter.The
resting sphincter pressure was deﬁned as the highest pressure
recorded among the 4 channels. The subject was asked to
squeeze the anal sphincter as ﬁrmly as possible and maintain
it for 25 seconds; this was repeated 5 times. The maximum
pressure recorded under these conditions was deﬁned as
the maximum squeeze pressure in mmHg. The subject was
then asked to strain (or bear down) for 25 seconds; this
was repeated 5 times. The maximum intrarectal pressure
recorded from the most distal sensor (located farthest away
fromtheanus) duringstraining wasdeﬁnedastheintrarectalISRN Gastroenterology 3
pressure, in mmHg. The residual pressure recorded from the
sensors at the high pressure (anal sphincter) zone, during
straining, was deﬁned as the residual anal sphincter pressure,
in mmHg.
The RAIR (i.e., relaxation of internal anal sphincter
duringrectaldistension)was elicitedbystepwise incremental
ﬁlling and emptying of the rectal distension balloon (by
10mL each step), placed in the rectal ampulla. The RAIR
threshold, determined as the minimum volume at which the
reﬂex could be elicited was then measured. The threshold
of rectal sensitivity deﬁned as the smallest volume of the
balloondistensionthatcouldbeperceivedbythesubject,was
determined by quickly inﬂating the distending balloon with
air (phasic distension) ranging from 10mL to 60mL.
Ramp distension was performed for the assessment of
(1) the ﬁrst sensation to ramp distension, (2) the urge to
defecate, which was deﬁned as the least volume to induce
an urge to defecate, and (3) the maximum tolerable volume,
which was deﬁned as the maximum volume tolerated by
the subject by verbal rapport. At the end of the sensation
test, the balloon was deﬂated and the catheter removed.
The Polygram Net Software (Medtronic A/S, Kobenhavn
S, Denmark) was used to determine various parameters of
anorectal motility.
2.2.2. Rectal Compliance and Visceral Sensation Tests. This
test was done at the completion of the above anorectal
motility/sensation test. A barostat catheter (MUI Scien-
tiﬁc, Mississauga, ON, Canada) that was attached with a
lubricated polyethylene bag (Pillow Type Rectal Barostat
Balloon, capacity 600mL; MUI Scientiﬁc, Mississauga, ON,
Canada), was inserted into the rectum [22]. The catheter
was positioned so that the middle of the balloon was located
approximately 10cm from the anal verge. The bag was then
unfolded by transiently inﬂating it with 50mL of air and
then deﬂating it completely. The catheter was connected to
a barostat (Synectics Visceral Stimulator, Synectics Medical,
Stockholm, Sweden). Following a 10-min adaptation period,
tests for visceral sensation and rectal compliance were
undertaken. For the determination of visceral sensation
(pain or discomfort), automated ramp inﬂation was used
with a step of 20mL starting from 20mL, and a step of
50mL starting from 100mL to a maximum of 500mL or
the maximal tolerable volume (constant volume mode). The
distension at each level was maintained for 45s, followed by
a 30s period of no distension. The rectal pressure and intra-
balloon volume at each level were recorded. The subject was
asked to mark the discomfort level on VAS (0–100mm) at
each level.
The balloon was then immediately deﬂated and the
following protocolwas followed to testfor rectal compliance.
Phasic distension of the balloon was performed in incre-
ments of 5mmHg at a starting baseline of 10mmHg to a
maximum of 60mmHg, or the maximum tolerance by the
subject (constant pressure mode). The distension at each
level was maintained for 45s, followed with a 30s period
of 5mmHg distension. The volume at each of the above
pressures was recorded. The volume was averaged over the
last 30s of each pressure level. A volume-pressure curve was
generated for each subject. Rectal compliance, deﬁned as the
linear slope of the volume-pressure curve was obtained [22].
2.3. Scoring of Anorectal Motility/Sensation Abnormalities.
Since motility/sensory dysfunctions in SSc are diverse, a
special scoring system was developed to include all ab-
normalities observed in the anorectal motility and sensa-
tion tests, deﬁned as follows: (1) abnormal compliance:
<20mmHg/mL; (2) abnormal RAIR: absence of RAIR at a
rectal distension volume of 30mL or higher; (3) abnormal
resting pressure of the anal sphincter: <40mmHg, (4)abnor-
mal squeeze pressure of the anal sphincter: <80mmHg; (5)
abnormal sensations, including (a) ﬁrst sensation threshold:
>30mL, (b) urge to defecate threshold: <80mL and (c)
maximum tolerable volume threshold: <200mL [23, 24].
Each of these abnormalities was assigned one point and
the total score was derived for each subject, with a possible
maximum score of 7.
2.3.1. Questionnaires of Quality of Life and GI Symptoms
Health-Related SF-36 Instrument (Version 1.0). This mea-
sures nonorgan speciﬁc quality of life (QoL) and has been
validated in SSc patients, normal populations and in other
health conditions [25–29]. Raw SF-36 domain scores and
physicalcomponentsummary (PCS)andmental component
summary (MCS) from our study were converted to version
2.0, using a 2.0 conversion kit (SF Health Outcomes Scoring
Software, QualityMetric Incorporated, Lincoln, RI, USA).
The converted data can then be compared with normative
data for the US populationand otherstudy populations. The
recall on the SF-36 items was 4 weeks.
GI Dysmotility Questionnaire (GIDQ). This was designed
to assess GI related symptoms and GI-related quality of
life, based on previous literature [30, 31]. The GIDQ or
parts of it had been used in previous studies [16, 17,
32, 33] and is presented elsewhere [33]. We designed and
used the GIDQ as at the time of this study, a validated
GI dysmotility symptoms questionnaire for SSc patients
was not available. The GIDQ includes 48 items including
questions on GI speciﬁc symptoms, including presence,
frequency and intensity of symptoms and their eﬀects on
the subject’s normal daily activities during the last week.
This questionnaire also queried issues related to perceived
functioning and quality of life. Patient responses included
“yes or no”answers and scoring on visual analog scales (VAS,
range = 1–7) for frequency of symptoms (days/week) and
subjective intensity of the symptom (0–100mm).
2.4. Scoring of Anorectal Symptoms. To investigate possible
correlation between anorectal motility/sensory abnormali-
ties and anorectal symptoms, two overall scoring systems
were used to assess anorectal symptoms, inferred from the
symptoms queried in the GIDQ, namely, the following:
fecal incontinence, hard stool, rectal fullness, incomplete
bowel movement and bleeding due to straining. The ﬁrst4 ISRN Gastroenterology
scoring system was based on the frequency of symptoms
(the anorectal symptom frequency score), in which the
weekly frequency of each of the 5 anorectal symptoms
was summated for each subject. The maximum score was
35/subject (5 symptoms, 7 days a week each). The second
scoring system was based on the prevalence of symptoms
(the anorectal symptom prevalence score), in which each
symptom was gradedas 0for absenceand1for presence.The
maximum score was 5/subject.
2.5. Statistical Analysis. All data are presented as mean ±
SEM. Unpaired Student’s t-test was used to assess the dif-
ference in each of parameters of anorectal motility between
the SSc patients and the normal controls. The strength of
the association between SSc and the absence of cutaneo-anal
reﬂexwasexpressedasoddsratio(OR),with95%conﬁdence
interval, calculatedby ChiSquareanalysis (GraphPad Prism-
LaJolla, CA,USA).Correlation wasassessed using Spearman
Rank Order analysis (SPSS 17.0 for Windows—Chicago, Ill,
USA). A P value <.05 was considered signiﬁcant.
3.Results
3.1. QoL and GI Symptoms. The demographics of the study
populations are shown in Table 1. There was a good match
in age, sex, and race between the patients and the healthy
controls. At the time of the study, no patient was using
laxatives, and only one was under corticosteroid treatment.
S S cp a t i e n t sh a dl o wQ O La n dm a r k e do v e r a l lG Is y m p t o m s .
Self-reported prevalence of anorectal symptoms for the SSc
patients are shown in Table 2. All SSc patients reported at
least one anorectal symptom and 50% of the SSc patients
had two or more anorectal symptoms at least once a week.
Self-reported frequency of anorectal symptoms for the SSc
patients are shown in Table 3.
3.2. Anorectal Motility. Table 4 shows the mean values
of measurements reﬂecting anorectal functions in the SSc
patients and normal controls. The cutaneo-anal reﬂex was
absent in 38% of patients (OR = 3.7; P = .03). The resting
and squeeze pressures of the anal sphincter, and the intrarec-
talpressure duringstraining werealllowerintheSScpatients
thanthenormalcontrols(P ≤ .01foreach comparison).The
thresholdvolumeofrectaldistensiontoinduceRAIRwasnot
signiﬁcantly diﬀerent in the SSc patients compared to the
normal controls (P = .1); however, in one SSc patient, the
RAIRwas not elicited even at 60mL. This is the same patient
that showed highest scores in symptom frequency, symptom
prevalence and anorectal motility/sensation abnormality
scores. All anorectal sensations had shown to be decreased in
the SSc patients compared to the normal controls. There was
signiﬁcant decrease in the threshold for the ﬁrst sensation by
39%,theurgetodefecateby21%andthemaximumtolerable
volume by 31% in the SSc patients compared to the normal
controls.
Rectal compliance was signiﬁcantly lower in the SSc
patients compared to the normal controls. This is shown
by the reduced β (representing the half-max volume on the
Rectal compliance curve in SSc patients and
controls
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Figure 1: Rectal compliance curve in SSc patients versus controls.
As shown,rectal compliancewas signiﬁcantlylower versus controls.
In SSc patients, rectal volumes were signiﬁcantly lower versus
controls at 20mmHg, and 25mmHg (∗P = .04 and .05, resp.).
pressure-volume curve, a 24% reduction, P = .05), P1/2
(representing the overall shape of the compliance curve, P =
.03)andPmax (representing the maximum tolerated pressure,
a 24% reduction, P = .05). Figure 1 shows rectal compliance
curves in the SSc patients and the normal controls. Rectal
volumes were signiﬁcantly lower to the applied balloon
pressures in the SSc patients compared to the controls at
20mmHg (a 33% reduction, P = .04) and 25mmHg
(a 23% reduction, P = .05). There were no signiﬁcant
diﬀerences between the SSc patients and the normal controls
in the reported VAS scores (for abdominal pain and urge
to defecate) at any balloon distension level up to 30mmHg.
It is worth noting that 5SSc patients could not tolerate
rectal balloon distension at any pressures >30mmHg, thus
the reporting for the urge to defecate and abdominal pain
due to rectal distension was only obtained at a pressure of
30mmHg or lower in these patients. Three patients had
modestly higher VAS scores for pain and urge to defecate
than the normal controls at pressures >than 35mmHg (P =
NS, not shown).
3.3. Correlation of Anorectal Motorand Sensory Abnormalities
and Anorectal Symptoms. Based on our scoring system, all
of the SSc patients (100%) had anorectal motility/sensation
abnormalities (Table 5). Figure 2 demonstrates the correla-
tion between anorectal motility/sensation abnormality score
and the anorectal symptom scores in the SSc patients. The
anorectal motility/sensation abnormality score were signiﬁ-
cantly and robustly correlated with the anorectal symptom
frequency score (rs = 0.78; P = .01—Figure 2(a))a n d
marginally correlated to the anorectal symptom prevalence
score (r = 0.595; P = .06—Figure 2(b)). Interestingly, in
SSc patients, the abdominal pain VAS score was inversely
correlated with intrarectal balloon volume at 20mmHg
(rs =− 0.53; P = .04) and 25mmHg (rs =− 0.49; P =
.05), suggesting that reduced rectal compliance might cause
abdominal pain.ISRN Gastroenterology 5
Table 2: Prevalence of anorectal symptoms self-reported by the SSc patients. +: Yes; −: No; BM: bowel movement.
Hard stools Incomplete BM PR bleeding Rectal fullness after BM Stool incontinence Total anorectal symptom score
Patient 1 −−+ −− 1
Patient 2 −−− − − 0
Patient 3 −−− − +1
Patient 4 − + − + − 2
Patient 5 − ++ −− 2
Patient 6 + + − + − 3
Patient 7 + + − ++ 4
Patient 8 + −− − − 1
Sum 3 4 2 3 2
Percentage 37.5% 50% 25% 37.5% 25%
Table 3: Frequency (days/week) of anorectal symptoms self-reported by the SSc patients. BM: bowel movement.
Hard stools Incomplete BM PR bleeding Rectal fullness after BM Stool incontinence Total anorectal symptom score
Patient 1 0 0 3 0 0 3
Patient 2 0 0 0 0 0 0
Patient 3 0 0 0 0 3 3
Patient 4 0 1 0 1 0 2
Patient 5 0 1 4 0 0 5
Patient 6 5 1 0 1 0 7
Patient 7 7 1 0 1 2 11
Patient 8 1 0 0 0 0 1
Table 4: Anorectal measurements for the SSc patients and the controls.
Variables SSc patients Controls P value
Manometry
Max. anal resting pressure (mmHg) 27.5 ±54 8 .8 ±4 .002
Max. squeeze pressure (mmHg) 71.8 ±14 97.5 ±5. 0 5
% increase in anal sphincter pressure during squeeze (mmHg) 32.3 ±55 0 .6 ±5. 0 1
Maximum intrarectal pressure (mmHg) 45.5 ±66 7 .5 ±5. 0 1
Residual anal sphincter pressure during straining (mmHg) 19.6 ±82 9 .5 ±6. 1
Least volume to induce RAIR (mL) 25.0 ±61 7 .5 ±3. 1 3
Threshold for 1st sensation (mL) 23.8 ±53 8 .8 ±6. 0 3
Threshold for Urge to defecate (mL) 73.8 ±13 93.8 ±7. 0 4
Maximum tolerable volume (mL) 108.8 ±14 156.3 ±13 .01
Compliance
Kappa (instantaneous slope of the curve) 1.1 ±01 .2 ±0. 4
Beta (overall shape of the curve) 26.4 ±43 4 .8 ±3. 0 5
P1/2 (half-max volume on pressure-volume curve - mmHg) 16.8 ±22 2 .0 ±2. 0 3
Pmax (maximum tolerated pressure - mmHg) 33.1 ±24 2 .1 ±4. 0 5
There was a marginal correlation between the anorectal
motility/sensation abnormality score and the overall GIDQ
scores (rs = 0.69; P = .058). There was no correlation
between the anorectal motility/sensation abnormality score
and QoL (r =− 0.3; P = .5a n dr =− 0.1; P = .8f o rP C S
and MCS, respectively).
4.Discussion
This study demonstrated the following: (1) patients with
SSc showed severe anorectal motility and sensation abnor-
malities, including reduced resting and squeeze pressures
of the anal sphincter, reduced rectal pressure during strain,6 ISRN Gastroenterology
Table 5: Anorectal motility/sensationabnormalityscoring system. +: Yes; −:N o .
AbnormalPressures Abnormal sensations
Abnormal
compliance
Absence of
RAIR up to
30mL
Resting Squeeze
First
sensation
threshold
Urge to
defecate
Maximum
tolerable
volume
Anorectal
motil-
ity/sensation
abnormality
scores
Patient 1 + − + −−++4
Patient 2 −−++−−−2
P a t i e n t 3 +++−−++5
Patient 4 + + −−+ −−3
Patient 5 −−−+++− 3
P a t i e n t 6 +++++++7
Patient 7 + − ++− ++5
Patient 8 + + −−+ −−3
S u m 6454454
Percentage 75% 50% 62.5% 50% 50% 62.5% 50%
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Figure 2: The correlation between anorectal motility/sensation abnormality score and the anorectal symptom scores in the SSc patients.
(a) Correlation of the anorectal motility/sensation abnormality score with the anorectal symptom frequency score in the SSc patients (r =
0.78; P = .01). (b) Correlation of the anorectal motility/sensation abnormality score with the total anorectal symptom prevalence score in
the SSc patients (r = 0.595; P = .06).
impaired rectal compliance and reduced ﬁrst sensation
threshold, urge to defecate, and tolerance to maximum
rectal distension and (2) the anorectal motility/sensation
abnormality score was robustly correlated with the anorec-
tal symptom frequency score and was marginally corre-
lated with the anorectal symptom prevalence score in SSc
patients.
In the present study, we were able to prove a correlation
between the anorectal motility/sensation abnormality score
and the anorectal symptom frequency score. To the best of
our knowledge, our study was the ﬁrst to demonstrate a sig-
niﬁcant correlation between the anorectal motility/sensation
abnormality score and the anorectal symptom frequency
score. This result was based on calculations deduced form
our scoring systems, and it suggests that the overall anorectal
symptoms may be predictive of overall anorectal motil-
ity/sensation dysfunction in SSc patients. Researchers have
been eagerly searching for a correlation between anorectal
symptoms and anorectal dysmotility to be able to predict
underlying anorectal dysmotility from SSc patient symp-
toms. Though the majority were generally unsuccessful,
however, in SSc patients, a negative correlation between
maximum tolerable volume and diarrhea [34]a n dap o s i t i v e
correlation between impaired RAIR and fecal incontinence
[35] were reported. Recently, we have reported a positive
correlation between the frequency of heartburn, an upper GI
symptom, and the changes in gastric myoelectrical activity, a
gastric function, as assessed by electrogastrography [16].
Anorectal symptoms were quite common among SSc
patients. Most SSc patients self-reported more than oneISRN Gastroenterology 7
anorectal symptom or experienced symptoms >2times/
week. Incomplete bowel movement was the most prevalent
symptom in the SSc patients. 25% of SSc patients reported
to have fecal incontinence; this was comparable to other
reports in which fecal incontinence ranges between 20%-
21%[34,36].Otherresearchers reported a higherpercentage
of incontinence (87.5%); however, this was in an SSc popu-
lation in which 50% suﬀered from associated rectal prolapse
[24]. Despite high prevalence of anorectal symptoms in
SSc patients, patients are often reticent or too embarrassed
to report these symptoms to their treating physicians, so
these symptoms are often undertreated [37]. Physicians
must be aware of the prevalence and frequency of anorectal
symptoms in order to elicit ongoing GI symptoms, so they
can target the patient problem with appropriate therapies.
Queries regarding changes in daily activities due to GI-
related problems may unmask signiﬁcant daily compromises
tocompensateforGIdysfunctions. Ourscoring systemoﬀers
a simple, feasible way to score patient symptoms to predict
underlying anorectal dysmotility.
It is known that SSc patients with severe GI involvement
experience considerably reduced QoL in physical and social
dimensions [17, 25], with increased mortality of up to
85% within 9 years, compared to patients with minor
GI complaints [38]. The Medical Outcome Survey Short-
Form 36 (SF-36) questionnaire has been used to assess
quality of life issues and the systemic involvement [25]. This
questionnaire can serve as an excellent tool for evaluation of
quality of life in this particular group of patients, hence our
use in the current study.
On the contrary, to date, there are no validated GI
symptom questionnaires targeting SSc patients which can
elucidate correlative links between GI-related symptoms and
GI dysmotility by conventional tests. Generally, GI symp-
toms have not been predictably correlative to the histologic
or physiologic severity of GI dysmotility or morbidity in
SSc [8, 39, 40]. We have written the GIDQ questionnaire
for GI symptoms that includes frequency of symptoms,
intensity of symptoms and quality of life issues. Our recent
studies showed that it can be used to determine the eﬀect of
treatment on GI symptoms as well as to correlate symptoms
togastric dysmotility [16,17].The GIDQhasbeenpublished
elsewhere [33].
The uniqueness of this study lies in our detailed com-
prehensive study of the anorectal functions. While other
researchers focused on one aspect of anorectal functions,
we provided a complete study of motor, sensory and
tonic functions of the anorectum in SSc patients. We
have reported decreased anorectal functioning by rectal
pressures, sensation and compliance, supporting neurologic
and myogenic contributions to GI dysfunction in the SSc
patients. The cutaneo-anal reﬂex was signiﬁcantly decreased
in SSc patients and three patients had a negative reﬂex,
implicating a possible autonomic neuropathy, as deduced
formthesigniﬁcant association oftheoddsratio.Itisevident
that autonomic dysfunction has been well recognized in SSc
patients [17, 41, 42]. Anorectal manometric measurements
were decreased in the SSc patients compared to normal
controls. Low resting pressure has been reported in 62.5% of
SSc patients; these results were comparable to other reports
[12]. In the SSc patients, though the maximum squeeze
pressure, a function of the skeletal external anal sphincter,
was lower than normal control, it remained within normal
range. This was in agreement with previous reports [12,
35, 36, 43–45] and is thought to be due to the selective
ﬁbrotic eﬀect of scleroderma on the smooth internal anal
sphincter [35]. RAIR, an intrinsic reﬂex to relax the internal
analsphincterinresponse torectaldistensionwas detectedin
50% of our SScpatients, comparable to otherreports [5, 24].
Only one patient showed no RAIR, even at the highest
distension volume. Absence, decrease or paradoxical RAIR is
common in SSc patients [36, 43, 44, 46]. Higher percentage
of impaired or absent RAIR has been also reported [35,
43–45]. Impaired or absence of RAIR is an indicator of
intrinsic rectal neural reﬂex disruption, similar to the early
reported duodenal neural reﬂex disruption in SSc patients
[47]. The thresholds for all sensations were lower in the SSc
patients than the normal control. In particular, maximum
tolerable volume, an index of the extent of involvement of
GI manifestations in SSc [34], was signiﬁcantly lower in
SSc patients in accordance of previous reports [24, 36, 43,
48–50]. This reduction in the maximum tolerable volume
reﬂectedlowercomplianceoftheanorectumandwasveriﬁed
by actual barostat measurements for rectal capacity and
compliance in the current study.
In the progression of pathological changes in the GI
t r a c ti nS S c ,i ti sh y p o t h e s i z e dt h a tt h en e u r o g e n i cs t a g e
occurs ﬁrst, followed by the myopathic/ﬁbrotic stage. We
have found three types of anorectal abnormalities in the
SSc patients: (1) reduced contractility or tone/pressure, (2)
reduced sensation, and (3) reduced compliance. Although
we cannot determine which of the pathological processes
is responsible for the anorectal abnormalities noted in the
current study, we suggest that the reported reduction in
anorectal contractility is possibly attributed to myopathy,
while the reduced sensation may be attributed to collagen
deposition and neuropathy or to muscle atrophy and ﬁbro-
sis, as suggested by Whitehead et al. [34]. The reduced
compliance is probably attributed to both the loss of rectal
elasticity, the resultant of collagen inﬁltration in the rectal
lamina propria, as shown in the autopsies of SSc patients
[48] or by loss of myotonic tone or by neuropathy. However,
reduced compliance with intact sensation (as inferred from
the presence of abdominal pain in response to balloon
distension) may suggest that the neurogenic stage may
be subsequent to the ﬁbrogenic stage or possibly that if
neurogenic processes are the initiating event, then the motor
neuropathy occurs before sensory deﬁcits. It is unknown
if the pathological stages of SSc GI dysfunction occur in
tandem or subsequently with increased GI related symptoms
or decreasing quality of life. The correlation of the presence
of abdominal pain with balloon distensions at 2 discrete
pressure points suggests they may occur in tandem.
In summary, we have developed an anorectal motil-
ity/sensation abnormality scoring system for SSc patients,
and thisspecial scoreisrobustlycorrelatedwith theanorectal
symptom frequency score and marginally correlated with
the anorectal symptom prevalence score. The scoring system8 ISRN Gastroenterology
proposedinthisstudymaybeusefulinpredictingunderlying
anorectal motility/sensation abnormalities in SSc patients.
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